舒泰神：继续推进注射用STSP-0601附条件批准上市工作

Core Viewpoint - The company is actively working on the conditional approval process for its injectable product STSP-0601, following a notification from the National Medical Products Administration regarding supplementary materials [1] Group 1: Company Actions - The company received a notification from the National Medical Products Administration's Drug Evaluation Center regarding the supplementary materials for the STSP-0601 project [1] - The company is organizing relevant departments to fulfill the requirements of the notification and expedite the submission of the supplementary materials [1] - The time taken for the applicant to submit supplementary materials will not be counted towards the drug evaluation timeline [1] Group 2: Future Updates - The company advises stakeholders to pay attention to subsequent regular reports and project progress announcements for updates on the STSP-0601 project [1]